CVS Health Corp.
Healthcare / Pharmacy RetailFounded 1963- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
CVS Health Corp.
Financial Performance
Last reviewed: July 2025 · By Swet Parvadiya
Revenue
$372B
Market Cap
$65.0B
Net Income
$4.6B
Employees
300,000
In 2014, CVS Health voluntarily removed all tobacco products from its more than 7,600 stores — forfeiting approximately $2 billion in annual revenue. The 2018 Aetna acquisition for $69 billion — the largest healthcare deal in U.S. History — grafted one of America's oldest health insurers onto what had been primarily a pharmacy chain. Revenue reached $372 billion in 2024. Net income was $4.6 billion — a 1.2% margin on 300 million customer interactions. CVS Health's revenue has grown consistently: $292 billion in 2021, $322 billion in 2022, $358 billion in 2023, $372 billion in 2024. Net income of $4.6 billion on $372 billion in revenue — a 1.2% margin — looks thin but reflects the economics of the PBM and insurance businesses, which generate large revenue volumes at low margins rather than high-margin product sales. The $65 billion market capitalization at roughly 14x earnings implies moderate confidence in the integrated model's ability to generate improving margins as the Medicare Advantage losses stabilize. For $69 billion, CVS acquired an insurance company with roots tracing to 1853 and a membership base of tens of millions of Americans.
Revenue Trend Analysis
YoY Change
+4%
4-Year CAGR
+8.5%
Peak Year
2024
Trend
Consistent Growth
CVS Health Corp. has reported revenue across 5 fiscal years, compounding at +8.5% annually over 4 years. The most recent year saw a 4% increase versus the prior year. Revenue peaked in 2024 at $372.0B. Out of 4 reported periods, 4 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2024 | $372.0B | $4.6B | +4.0% |
| FY2023 | $357.8B | — | +10.9% |
| FY2022 | $322.5B | — | +10.4% |
| FY2021 | $292.1B | — | +8.7% |
| FY2020 | $268.7B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
CVS Health Corp.'s $4.6 billion 2024 net income on $372 billion revenue represents minimal 1.2% net margin, dramatically reduced from prior years reflecting substantial Medicare Advantage business challenges at Aetna subsidiary generating significant earnings pressure. The financial performance reflects healthcare industry economics with thin margins across multiple segments, plus 2024-specific challenges including elevated medical loss ratios, continued regulatory pressures, and various other operational factors. Operating cash flow generation of approximately $9 billion supports continued dividend payments ($2.66 annual dividend, 4%+ yield), continued debt service on approximately $59 billion total debt, capital expenditure supporting various operational requirements, and various other capital deployment needs. Recent earnings recovery depends on continued Medicare Advantage business improvement through 2025 pricing actions plus continued operational execution across various healthcare segments. Future profitability depends on continued strategic execution, healthcare industry dynamics, and various competitive factors affecting consolidated business performance.
CVS Health Corp. carries approximately $59 billion in long-term debt primarily through 2018 Aetna acquisition ($69 billion transaction substantially debt-financed), creating elevated leverage that management has gradually reduced through operating cash flow generation across multiple years. Net debt to EBITDA ratio of approximately 4x exceeds industry comfort levels reflecting continued strategic constraint affecting capital deployment flexibility. Interest expense of approximately $2.5 billion annually represents significant operational cost requiring continued operational cash generation supporting debt service. Strategic capital structure decisions navigate competing priorities including continued debt reduction, dividend maintenance (current dividend payments approximately $3 billion annually), continued operational reinvestment supporting various healthcare segments, and selective M&A activity supporting strategic positioning. Recent strategic challenges including 2024 Medicare Advantage business pressures have limited deleveraging pace versus initial post-Aetna acquisition plans. Future capital structure depends on continued operational performance and various strategic factors affecting capital deployment options.
CVS Health Corp. balances substantial dividend commitment ($2.66 annual dividend, 4%+ yield representing approximately $3 billion annual payments) with continued strategic investment requirements supporting various healthcare operations through challenging operational environment. The dividend policy emphasises continued payments supporting income-oriented shareholder base, with continued strategic flexibility supporting various operational priorities. Capital allocation framework prioritises continued operations support including Medicare Advantage business stabilisation, ongoing integration efforts supporting Aetna operational improvements, debt reduction supporting capital structure strengthening, and selective strategic investments. Recent capital allocation has emphasised operational priorities over aggressive shareholder returns reflecting continued financial challenges. Future capital allocation depends on continued operational performance through Medicare Advantage business recovery, continued debt reduction trajectory, and various other strategic factors. The continued dividend commitment supports investor confidence through strategic transition period requiring continued operational execution and recovery from 2024 challenges.
CVS Health Corp.'s 2024 financial performance demonstrated extreme sensitivity to Medicare Advantage business dynamics with Aetna subsidiary generating significant earnings shortfall through elevated medical loss ratios. Medicare Advantage represents approximately $30+ billion of Aetna's $44 billion in revenue with substantial growth potential through continued senior healthcare market expansion, but also significant earnings volatility through medical cost utilisation dynamics, regulatory rate changes, and competitive market intensity. Strategic responses include continued Medicare Advantage pricing actions for 2025 supporting financial recovery, operational efficiency improvements through various initiatives, member service enhancements supporting retention, and various other strategic moves. Continued regulatory environment affecting Medicare Advantage including Inflation Reduction Act drug price provisions, continued rate methodology changes, and various other regulatory factors creates ongoing financial sensitivity. Future Medicare Advantage performance critically affects overall CVS Health financial trajectory requiring continued operational discipline and strategic execution through ongoing competitive dynamics.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "CVS Health Corp. Revenue & Financials." CorpDigest, https://corpdigest.com/company/cvs-health/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>CVS Health Corp. reported $372B in revenue (FY2024).</strong><br>Source: <a href="https://corpdigest.com/company/cvs-health/financials" target="_blank" rel="noopener">CorpDigest — CVS Health Corp. financials</a></div>